{"id":"actoplus-met","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Edema"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Lactic acidosis (rare)"}]},"_chembl":null,"_dailymed":{"setId":"42e49120-6f3f-11db-9fe1-0800200c9a66","title":"ACTOPLUS MET (PIOGLITAZONE AND METFORMIN HYDROCHLORIDE) TABLET, FILM COATED [TAKEDA PHARMACEUTICALS AMERICA, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pioglitazone acts as a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, enhancing insulin sensitivity in muscle and adipose tissue. Metformin decreases hepatic glucose production and improves peripheral glucose uptake. Together, they address multiple pathophysiologic defects in type 2 diabetes through complementary mechanisms.","oneSentence":"Actoplus Met combines pioglitazone (a thiazolidinedione that increases insulin sensitivity) with metformin (a biguanide that reduces hepatic glucose production) to improve glycemic control in type 2 diabetes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:17:51.042Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07289750","phase":"PHASE4","title":"The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD","status":"NOT_YET_RECRUITING","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2026-05-01","conditions":"T2DM, MAFLD","enrollment":80},{"nctId":"NCT01471808","phase":"PHASE4","title":"Effects of Different Early Intensive Therapies on Long-term β-cell Function","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2011-10","conditions":"Diabetes Mellitus, Type 2","enrollment":264},{"nctId":"NCT01107717","phase":"PHASE4","title":"Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2009-01","conditions":"Diabetes","enrollment":318},{"nctId":"NCT04419337","phase":"PHASE2","title":"Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2019-09-15","conditions":"Diabetes Mellitus, Stroke","enrollment":200},{"nctId":"NCT02917629","phase":"PHASE2","title":"ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-05-31","conditions":"Oral Cavity Neoplasm, Oropharyngeal Neoplasm, Stage 0 Oral Cavity Squamous Cell Carcinoma American Joint Committee on Cancer (AJCC) v6 and v7","enrollment":6},{"nctId":"NCT05591235","phase":"PHASE3","title":"Effect of Metformin, Dapagliflozin, Combination of Metformin and Pioglitazone in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2022-11","conditions":"Type2diabetes, Insulin Resistance","enrollment":60},{"nctId":"NCT05521633","phase":"PHASE3","title":"Comparison of the Effects of Metformin and Pioglitazone on Liver Enzymes and Ultrasound Changes in Non-Diabetic Non-Alcoholic Fatty Liver","status":"COMPLETED","sponsor":"King Edward Medical University","startDate":"2019-06-06","conditions":"NAFLD","enrollment":96},{"nctId":"NCT05519813","phase":"PHASE4","title":"Effects of Pioglitazone Combined With Metformin on Gonadal and Metabolic Profiles in Chinese Nonobese PCOS Patients.","status":"UNKNOWN","sponsor":"Bing He","startDate":"2022-01-01","conditions":"Polycystic Ovary Syndrome","enrollment":60},{"nctId":"NCT02787551","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-06","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT04867252","phase":"PHASE2","title":"Effects of Combined Resveratrol and Myo-inositol on Altered Metabolic, Endocrine Parameters and Perceived Stress in Patients With Polycystic Ovarian Syndrome","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2021-05-03","conditions":"PCOS","enrollment":88},{"nctId":"NCT03452267","phase":"PHASE2, PHASE3","title":"Insulin Signaling in Skeletal Muscle","status":"WITHDRAWN","sponsor":"Wayne State University","startDate":"2019-09-01","conditions":"Insulin Sensitivity","enrollment":""},{"nctId":"NCT04392557","phase":"PHASE4","title":"Anti-inflammatory Status in DM2 Treated Patients","status":"UNKNOWN","sponsor":"University of Catanzaro","startDate":"2020-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":36},{"nctId":"NCT03796975","phase":"PHASE4","title":"Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease","status":"COMPLETED","sponsor":"Xijing Hospital","startDate":"2018-06-28","conditions":"Type 2 Diabetes Mellitus, Non-alcoholic Fatty Liver Disease, Efficacy","enrollment":120},{"nctId":"NCT03117517","phase":"EARLY_PHASE1","title":"Treatment With Metformin and Combination of Metformin and Pioglitazone in Polycystic Ovarian Syndrome","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2017-03-20","conditions":"Polycystic Ovarian Syndrome","enrollment":106},{"nctId":"NCT04113889","phase":"PHASE2","title":"Effects of Triple Drug Cocktail Therapy on Metabolic, Endocrine Alterations and Perceived Stress in Patients With Poly Cystic Ovary Syndrome","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2019-10-15","conditions":"PCOS","enrollment":147},{"nctId":"NCT02689843","phase":"EARLY_PHASE1","title":"Effects of Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Inflammatory Markers in PCOS","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2018-02-01","conditions":"Polycystic Ovary Syndrome","enrollment":90},{"nctId":"NCT04141163","phase":"PHASE1, PHASE2","title":"Metformin in Patients With Fragile X","status":"UNKNOWN","sponsor":"Rowan University","startDate":"2019-10-29","conditions":"Fragile X Syndrome","enrollment":40},{"nctId":"NCT02072096","phase":"PHASE4","title":"A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2014-02","conditions":"Diabetes Mellitus, Type 2","enrollment":192},{"nctId":"NCT03757923","phase":"PHASE1, PHASE2","title":"Comparison of Metformin and Pioglitazone in Regulating Menstrual Irregularities and Hyperandrogenism","status":"UNKNOWN","sponsor":"Dow University of Health Sciences","startDate":"2018-06-18","conditions":"Menstrual Irregularities, Hyperandrogenism","enrollment":110},{"nctId":"NCT00232583","phase":"NA","title":"Preservation of Beta-cell Function in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2003-11","conditions":"Type 2 Diabetes Mellitus","enrollment":58},{"nctId":"NCT02733679","phase":"PHASE4","title":"Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone","status":"COMPLETED","sponsor":"NHS Tayside","startDate":"2016-09-29","conditions":"Ataxia-Telangiectasia","enrollment":27},{"nctId":"NCT02875821","phase":"PHASE4","title":"Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-04-26","conditions":"Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD)","enrollment":44},{"nctId":"NCT00885352","phase":"PHASE3","title":"Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-15","conditions":"Type 2 Diabetes Mellitus","enrollment":313},{"nctId":"NCT00972283","phase":"PHASE3","title":"Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-09-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1006},{"nctId":"NCT00097279","phase":"PHASE3","title":"Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-08","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":230},{"nctId":"NCT01759823","phase":"PHASE2, PHASE3","title":"Bone Marrow Derived Stem Cell Transplantation in T2DM","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2012-12","conditions":"Type 2 Diabetes Mellitus","enrollment":30},{"nctId":"NCT01065298","phase":"","title":"Efficacy Of Autologous Bone Marrow Derived Stem Cell Transplantation In Patients With Type 2 Diabetes Mellitus-2","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2009-11","conditions":"Type 2 Diabetes Mellitus","enrollment":30},{"nctId":"NCT01909141","phase":"EARLY_PHASE1","title":"Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS","status":"COMPLETED","sponsor":"Cairo University","startDate":"2013-08","conditions":"Polycystic Ovary Syndrome, Infertility","enrollment":100},{"nctId":"NCT02341703","phase":"EARLY_PHASE1","title":"Ovulation Induction in Clomiphene Citrate Resistant PCO Women","status":"COMPLETED","sponsor":"Cairo University","startDate":"2015-02","conditions":"Polycystic Ovary Syndrome, Infertility","enrollment":100},{"nctId":"NCT01064687","phase":"PHASE3","title":"A Study in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-02","conditions":"Diabetes Mellitus, Type 2","enrollment":978},{"nctId":"NCT02027103","phase":"NA","title":"Metformin and Pioglitazone Effects on Fetuin-A and Osteoprotegrin Concentrations in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2012-01","conditions":"Type 2 Diabetes Mellitus","enrollment":102},{"nctId":"NCT00443755","phase":"PHASE2","title":"Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2005-08","conditions":"Type 2 Diabetes, Insulin Resistance, Metabolic Syndrome","enrollment":28},{"nctId":"NCT01963663","phase":"NA","title":"Metformin and Pioglitazone Effects on YKL-40 Concentrations in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2012-11","conditions":"Type 2 Diabetes Mellitus","enrollment":84},{"nctId":"NCT01106690","phase":"PHASE3","title":"The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-06","conditions":"Diabetes Mellitus, Type 2","enrollment":344},{"nctId":"NCT01895569","phase":"PHASE4","title":"Triple Therapy in Type 2 Diabetic Patients","status":"UNKNOWN","sponsor":"University of Pavia","startDate":"2013-06","conditions":"Type 2 Diabetes Mellitus","enrollment":64},{"nctId":"NCT01800227","phase":"PHASE1","title":"Bioequivalence Study of Torrent Pharmaceuticals Ltd's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT01800240","phase":"PHASE1","title":"Bioequivalence Study of Torrent Pharmaceuticals Ltd's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT01593371","phase":"NA","title":"Comparison of Metformin and Pioglitazone Effects on Adipokines Concentrations in Newly Diagnosed Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2011-07","conditions":"Type 2 Diabetes Mellitus","enrollment":98},{"nctId":"NCT00727857","phase":"PHASE3","title":"Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-06","conditions":"Diabetes Mellitus","enrollment":600}],"_emaApprovals":[],"_faersSignals":[{"count":310,"reaction":"BLADDER CANCER"},{"count":114,"reaction":"BLOOD GLUCOSE INCREASED"},{"count":104,"reaction":"NAUSEA"},{"count":82,"reaction":"WEIGHT DECREASED"},{"count":59,"reaction":"DEATH"},{"count":52,"reaction":"FLUSHING"},{"count":46,"reaction":"BLOOD GLUCOSE DECREASED"},{"count":46,"reaction":"DIZZINESS"},{"count":42,"reaction":"DRUG INEFFECTIVE"},{"count":42,"reaction":"DYSPNOEA"}],"_approvalHistory":[{"date":"20091021","type":"SUPPL","sponsor":"TAKEDA PHARMS USA","applicationNumber":"NDA021842"},{"date":"20061104","type":"SUPPL","sponsor":"TAKEDA PHARMS USA","applicationNumber":"NDA021842"},{"date":"20130815","type":"SUPPL","sponsor":"TAKEDA PHARMS USA","applicationNumber":"NDA021842"},{"date":"20090914","type":"SUPPL","sponsor":"TAKEDA PHARMS USA","applicationNumber":"NDA021842"},{"date":"20120517","type":"SUPPL","sponsor":"TAKEDA PHARMS USA","applicationNumber":"NDA021842"},{"date":"20090104","type":"SUPPL","sponsor":"TAKEDA PHARMS USA","applicationNumber":"NDA021842"},{"date":"20171221","type":"SUPPL","sponsor":"TAKEDA PHARMS USA","applicationNumber":"NDA021842"},{"date":"20110804","type":"SUPPL","sponsor":"TAKEDA PHARMS USA","applicationNumber":"NDA021842"},{"date":"20070926","type":"SUPPL","sponsor":"TAKEDA PHARMS USA","applicationNumber":"NDA021842"},{"date":"20161212","type":"SUPPL","sponsor":"TAKEDA PHARMS USA","applicationNumber":"NDA021842"},{"date":"20100806","type":"SUPPL","sponsor":"TAKEDA PHARMS USA","applicationNumber":"NDA021842"},{"date":"20060928","type":"SUPPL","sponsor":"TAKEDA PHARMS USA","applicationNumber":"NDA021842"},{"date":"20060830","type":"SUPPL","sponsor":"TAKEDA PHARMS USA","applicationNumber":"NDA021842"},{"date":"20120517","type":"SUPPL","sponsor":"TAKEDA PHARMS USA","applicationNumber":"NDA021842"},{"date":"20140816","type":"SUPPL","sponsor":"TAKEDA PHARMS USA","applicationNumber":"NDA021842"},{"date":"20240628","type":"SUPPL","sponsor":"TAKEDA PHARMS USA","applicationNumber":"NDA021842"},{"date":"20120517","type":"SUPPL","sponsor":"TAKEDA PHARMS USA","applicationNumber":"NDA021842"},{"date":"20050829","type":"ORIG","sponsor":"TAKEDA PHARMS USA","applicationNumber":"NDA021842"},{"date":"20110804","type":"SUPPL","sponsor":"TAKEDA PHARMS USA","applicationNumber":"NDA021842"},{"date":"20161212","type":"SUPPL","sponsor":"TAKEDA PHARMS USA","applicationNumber":"NDA021842"}],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"actoplus met","genericName":"actoplus met","companyName":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","companyId":"the-fourth-affiliated-hospital-of-zhejiang-university-school-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Actoplus Met combines pioglitazone (a thiazolidinedione that increases insulin sensitivity) with metformin (a biguanide that reduces hepatic glucose production) to improve glycemic control in type 2 diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}